Summary

The global Anticancer Biologics market is projected to grow from US$ 111457 million in 2025 to US$ 214273 million by 2032, at a CAGR of 9.3% (2026-2032), driven by critical product segments and diverse end‑use applications.
Anticancer Biologics are a class of biologic medicines that use antibodies, proteins, cells, viruses, or other biologically derived substances as their primary active components to treat cancer through mechanisms such as specifically recognizing tumor-associated targets, modulating immune responses, directly eliminating tumor cells, blocking tumor growth signaling pathways, or altering the tumor microenvironment. Anticancer Biologics mainly include monoclonal antibodies, bispecific and multispecific antibodies, antibody-drug conjugates, cell therapies, cancer vaccines, and oncolytic virus therapies, and are widely used in the treatment of lung cancer, breast cancer, gastrointestinal cancers, hematologic cancers, and other malignant tumors.
Anticancer Biologics represent an important segment of modern cancer therapy and mainly include monoclonal antibodies, bispecific and multispecific antibodies, antibody-drug conjugates, cell therapies, cancer vaccines, and oncolytic virus therapies. Compared with conventional chemotherapy, Anticancer Biologics generally offer greater target specificity, more clearly defined mechanisms of action, and the ability to activate or modulate the immune system. They are widely used in the treatment of lung cancer, breast cancer, gastrointestinal cancers, hematologic cancers, and various other malignancies.
From an industry value-chain perspective, the upstream segment mainly includes cell lines, culture media, single-use bioreactors, chromatography media, filtration materials, pharmaceutical excipients, as well as key materials such as antibodies, payloads, and linkers. The midstream segment covers drug discovery, cell-line development, process development, drug-substance manufacturing, formulation, aseptic filling, quality control, and clinical development. Downstream demand mainly comes from general hospitals, oncology specialty hospitals, hematology treatment centers, and other specialized medical institutions. Antibody-based products are generally manufactured at scale through mammalian cell culture and bioreactor systems, with individual production lines ranging from several thousand liters to tens of thousands of liters in capacity, while cell therapies and cancer vaccines typically rely on smaller-batch, more flexible, and in some cases patient-specific manufacturing models.
The Anticancer Biologics industry is characterized by long development cycles, high technological barriers, stringent regulatory requirements, and substantial capital investment. Manufacturing costs are influenced by cell-culture productivity, protein expression levels, purification yields, raw material costs, production scale, and capacity utilization. Mature antibody products can generally achieve relatively attractive gross margins once large-scale production is established, while cell therapies, complex bispecific antibodies, and certain antibody-drug conjugates tend to carry higher manufacturing costs because of their more complicated production processes, smaller batch sizes, and stricter quality-control requirements. Advances in continuous manufacturing, single-use bioreactors, high-expression cell lines, and automated quality-control technologies are steadily improving manufacturing efficiency across the industry.
The competitive landscape is shaped by both large multinational pharmaceutical companies and biotechnology companies with differentiated technology platforms. Large pharmaceutical companies generally benefit from stronger capabilities in clinical development, global regulatory registration, commercialization, and large-scale manufacturing, while emerging biotechnology companies compete through innovative approaches such as bispecific antibodies, antibody-drug conjugates, cell therapies, and novel immuno-oncology targets. Chinese companies have developed rapidly in areas including PD-1/PD-L1 antibodies, bispecific antibodies, antibody-drug conjugates, and cell therapies, and are increasingly expanding into global markets through licensing agreements, co-development partnerships, and international clinical trials.
Looking forward, the Anticancer Biologics industry is expected to evolve from conventional single-target monoclonal antibodies toward bispecific and multispecific antibodies, next-generation antibody-drug conjugates, cell therapies, and combination treatments involving multiple mechanisms of action. Biomarker-based patient selection, precision treatment, subcutaneous formulations, long-acting formulations, and more efficient manufacturing processes are also expected to become increasingly important sources of clinical and commercial differentiation. As more biologic therapies move from later-line treatment into first-line, neoadjuvant, and adjuvant settings, Anticancer Biologics are expected to play an increasingly important role in the global cancer treatment landscape.
Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Anticancer Biologics market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
AbbVie Inc.
Johnson & Johnson
Novartis AG
Gilead Sciences, Inc.
Roche
Bristol-Myers Squibb Company
Amgen Inc.
AstraZeneca plc
Merck & Co., Inc.
Takeda Pharmaceutical Company Limited
Merck KGaA
Eli Lilly and Company
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
GSK plc
Regeneron Pharmaceuticals, Inc.
Innovent Biologics, Inc.
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Shanghai Junshi Biosciences Co., Ltd.
Akeso, Inc.
Shanghai Henlius Biotech, Inc.
RemeGen Co., Ltd.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Sino Biopharmaceutical Limited
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Jiangsu Alphamab Biopharmaceuticals Co., Ltd.
Segment by Type
Antibody Therapies
Antibody-Drug Conjugates (ADCs)
Cell Therapies
Cancer Vaccines and Oncolytic Viruses
Others
Segment by Target
Immune Checkpoint Targets
Solid Tumor-Associated Targets
Hematologic Tumor Targets
Angiogenesis-Related Targets
Others
Segment by Route of Administration
Intravenous Administration
Subcutaneous Administration
Cell Infusion
Intratumoral Administration
Others
Segment by Application
Lung Cancer
Breast Cancer
Hematologic Cancers
Gastrointestinal Cancers
Others
Segment by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Anticancer Biologics study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments
Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to Anticancer Biologics: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Anticancer Biologics Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Antibody Therapies
1.2.3 Antibody-Drug Conjugates (ADCs)
1.2.4 Cell Therapies
1.2.5 Cancer Vaccines and Oncolytic Viruses
1.2.6 Others
1.3 Market Segmentation by Target
1.3.1 Global Anticancer Biologics Market Size by Target, 2021 vs 2025 vs 2032
1.3.2 Immune Checkpoint Targets
1.3.3 Solid Tumor-Associated Targets
1.3.4 Hematologic Tumor Targets
1.3.5 Angiogenesis-Related Targets
1.3.6 Others
1.4 Market Segmentation by Route of Administration
1.4.1 Global Anticancer Biologics Market Size by Route of Administration, 2021 vs 2025 vs 2032
1.4.2 Intravenous Administration
1.4.3 Subcutaneous Administration
1.4.4 Cell Infusion
1.4.5 Intratumoral Administration
1.4.6 Others
1.5 Market Segmentation by Application
1.5.1 Global Anticancer Biologics Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Lung Cancer
1.5.3 Breast Cancer
1.5.4 Hematologic Cancers
1.5.5 Gastrointestinal Cancers
1.5.6 Others
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Anticancer Biologics Revenue Estimates and Forecasts (2021-2032)
2.2 Global Anticancer Biologics Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competitive Landscape
3.1 Global Anticancer Biologics Players’ Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2021-2026)
3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Players (2021 vs 2025)
3.2 Global Anticancer Biologics Companies Headquarters and Service Footprint
3.3 Key Player Market Share by Product Type
3.3.1 Antibody Therapies: Market Share by Key Players
3.3.2 Antibody-Drug Conjugates (ADCs): Market Share by Key Players
3.3.3 Cell Therapies: Market Share by Key Players
3.3.4 Cancer Vaccines and Oncolytic Viruses: Market Share by Key Players
3.3.5 Others: Market Share by Key Players
3.4 Global Anticancer Biologics Market Concentration and Dynamics
3.4.1 Global Market Concentration
3.4.2 Market Entry and Exit Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Product Segmentation
4.1 Global Anticancer Biologics Market by Type
4.1.1 Global Revenue by Type (2021-2032)
4.1.2 Global Revenue-Based Market Share by Type (2021-2032)
4.2 Global Anticancer Biologics Market by Target
4.2.1 Global Revenue by Target (2021-2032)
4.2.2 Global Revenue-Based Market Share by Target (2021-2032)
4.3 Global Anticancer Biologics Market by Route of Administration
4.3.1 Global Revenue by Route of Administration (2021-2032)
4.3.2 Global Revenue-Based Market Share by Route of Administration (2021-2032)
4.4 Key Product Attributes and Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Anticancer Biologics Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.1.2 Revenue-Based Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application

6 North America
6.1 North America Market Size (2021-2032)
6.2 North America Key Players’ Revenue in 2025
6.3 North America Anticancer Biologics Market Size by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Anticancer Biologics Market Size by Country
6.5.1 North America Revenue Trends by Country
6.5.2 US
6.5.3 Canada
6.5.4 Mexico

7 Europe
7.1 Europe Market Size (2021-2032)
7.2 Europe Key Players’ Revenue in 2025
7.3 Europe Anticancer Biologics Market Size by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Anticancer Biologics Market Size by Country
7.5.1 Europe Revenue Trends by Country
7.5.2 Germany
7.5.3 France
7.5.4 U.K.
7.5.5 Italy
7.5.6 Russia

8 Asia-Pacific
8.1 Asia-Pacific Market Size (2021-2032)
8.2 Asia-Pacific Key Players’ Revenue in 2025
8.3 Asia-Pacific Anticancer Biologics Market Size by Application (2021-2032)
8.4 Asia-Pacific Growth Accelerators and Market Barriers
8.5 Asia-Pacific Anticancer Biologics Market Size by Region
8.5.1 Asia-Pacific Revenue Trends by Region
8.6 China
8.7 Japan
8.8 South Korea
8.9 Australia
8.10 India
8.11 Southeast Asia
8.11.1 Indonesia
8.11.2 Vietnam
8.11.3 Malaysia
8.11.4 Philippines
8.11.5 Singapore

9 Central and South America
9.1 Central and South America Market Size (2021-2032)
9.2 Central and South America Key Players’ Revenue in 2025
9.3 Central and South America Anticancer Biologics Market Size by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Anticancer Biologics Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Market Size (2021-2032)
10.2 Middle East and Africa Key Players’ Revenue in 2025
10.3 Middle East and Africa Anticancer Biologics Market Size by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Anticancer Biologics Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Israel
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 AbbVie Inc.
11.1.1 AbbVie Inc. Corporation Information
11.1.2 AbbVie Inc. Business Overview
11.1.3 AbbVie Inc. Anticancer Biologics Product Features and Attributes
11.1.4 AbbVie Inc. Anticancer Biologics Revenue and Gross Margin (2021-2026)
11.1.5 AbbVie Inc. Anticancer Biologics Revenue by Product in 2025
11.1.6 AbbVie Inc. Anticancer Biologics Revenue by Application in 2025
11.1.7 AbbVie Inc. Anticancer Biologics Revenue by Geographic Area in 2025
11.1.8 AbbVie Inc. Anticancer Biologics SWOT Analysis
11.1.9 AbbVie Inc. Recent Developments
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Corporation Information
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson Anticancer Biologics Product Features and Attributes
11.2.4 Johnson & Johnson Anticancer Biologics Revenue and Gross Margin (2021-2026)
11.2.5 Johnson & Johnson Anticancer Biologics Revenue by Product in 2025
11.2.6 Johnson & Johnson Anticancer Biologics Revenue by Application in 2025
11.2.7 Johnson & Johnson Anticancer Biologics Revenue by Geographic Area in 2025
11.2.8 Johnson & Johnson Anticancer Biologics SWOT Analysis
11.2.9 Johnson & Johnson Recent Developments
11.3 Novartis AG
11.3.1 Novartis AG Corporation Information
11.3.2 Novartis AG Business Overview
11.3.3 Novartis AG Anticancer Biologics Product Features and Attributes
11.3.4 Novartis AG Anticancer Biologics Revenue and Gross Margin (2021-2026)
11.3.5 Novartis AG Anticancer Biologics Revenue by Product in 2025
11.3.6 Novartis AG Anticancer Biologics Revenue by Application in 2025
11.3.7 Novartis AG Anticancer Biologics Revenue by Geographic Area in 2025
11.3.8 Novartis AG Anticancer Biologics SWOT Analysis
11.3.9 Novartis AG Recent Developments
11.4 Gilead Sciences, Inc.
11.4.1 Gilead Sciences, Inc. Corporation Information
11.4.2 Gilead Sciences, Inc. Business Overview
11.4.3 Gilead Sciences, Inc. Anticancer Biologics Product Features and Attributes
11.4.4 Gilead Sciences, Inc. Anticancer Biologics Revenue and Gross Margin (2021-2026)
11.4.5 Gilead Sciences, Inc. Anticancer Biologics Revenue by Product in 2025
11.4.6 Gilead Sciences, Inc. Anticancer Biologics Revenue by Application in 2025
11.4.7 Gilead Sciences, Inc. Anticancer Biologics Revenue by Geographic Area in 2025
11.4.8 Gilead Sciences, Inc. Anticancer Biologics SWOT Analysis
11.4.9 Gilead Sciences, Inc. Recent Developments
11.5 Roche
11.5.1 Roche Corporation Information
11.5.2 Roche Business Overview
11.5.3 Roche Anticancer Biologics Product Features and Attributes
11.5.4 Roche Anticancer Biologics Revenue and Gross Margin (2021-2026)
11.5.5 Roche Anticancer Biologics Revenue by Product in 2025
11.5.6 Roche Anticancer Biologics Revenue by Application in 2025
11.5.7 Roche Anticancer Biologics Revenue by Geographic Area in 2025
11.5.8 Roche Anticancer Biologics SWOT Analysis
11.5.9 Roche Recent Developments
11.6 Bristol-Myers Squibb Company
11.6.1 Bristol-Myers Squibb Company Corporation Information
11.6.2 Bristol-Myers Squibb Company Business Overview
11.6.3 Bristol-Myers Squibb Company Anticancer Biologics Product Features and Attributes
11.6.4 Bristol-Myers Squibb Company Anticancer Biologics Revenue and Gross Margin (2021-2026)
11.6.5 Bristol-Myers Squibb Company Recent Developments
11.7 Amgen Inc.
11.7.1 Amgen Inc. Corporation Information
11.7.2 Amgen Inc. Business Overview
11.7.3 Amgen Inc. Anticancer Biologics Product Features and Attributes
11.7.4 Amgen Inc. Anticancer Biologics Revenue and Gross Margin (2021-2026)
11.7.5 Amgen Inc. Recent Developments
11.8 AstraZeneca plc
11.8.1 AstraZeneca plc Corporation Information
11.8.2 AstraZeneca plc Business Overview
11.8.3 AstraZeneca plc Anticancer Biologics Product Features and Attributes
11.8.4 AstraZeneca plc Anticancer Biologics Revenue and Gross Margin (2021-2026)
11.8.5 AstraZeneca plc Recent Developments
11.9 Merck & Co., Inc.
11.9.1 Merck & Co., Inc. Corporation Information
11.9.2 Merck & Co., Inc. Business Overview
11.9.3 Merck & Co., Inc. Anticancer Biologics Product Features and Attributes
11.9.4 Merck & Co., Inc. Anticancer Biologics Revenue and Gross Margin (2021-2026)
11.9.5 Merck & Co., Inc. Recent Developments
11.10 Takeda Pharmaceutical Company Limited
11.10.1 Takeda Pharmaceutical Company Limited Corporation Information
11.10.2 Takeda Pharmaceutical Company Limited Business Overview
11.10.3 Takeda Pharmaceutical Company Limited Anticancer Biologics Product Features and Attributes
11.10.4 Takeda Pharmaceutical Company Limited Anticancer Biologics Revenue and Gross Margin (2021-2026)
11.10.5 Company Ten Recent Developments
11.11 Merck KGaA
11.11.1 Merck KGaA Corporation Information
11.11.2 Merck KGaA Business Overview
11.11.3 Merck KGaA Anticancer Biologics Product Features and Attributes
11.11.4 Merck KGaA Anticancer Biologics Revenue and Gross Margin (2021-2026)
11.11.5 Merck KGaA Recent Developments
11.12 Eli Lilly and Company
11.12.1 Eli Lilly and Company Corporation Information
11.12.2 Eli Lilly and Company Business Overview
11.12.3 Eli Lilly and Company Anticancer Biologics Product Features and Attributes
11.12.4 Eli Lilly and Company Anticancer Biologics Revenue and Gross Margin (2021-2026)
11.12.5 Eli Lilly and Company Recent Developments
11.13 Ono Pharmaceutical Co., Ltd.
11.13.1 Ono Pharmaceutical Co., Ltd. Corporation Information
11.13.2 Ono Pharmaceutical Co., Ltd. Business Overview
11.13.3 Ono Pharmaceutical Co., Ltd. Anticancer Biologics Product Features and Attributes
11.13.4 Ono Pharmaceutical Co., Ltd. Anticancer Biologics Revenue and Gross Margin (2021-2026)
11.13.5 Ono Pharmaceutical Co., Ltd. Recent Developments
11.14 Pfizer Inc.
11.14.1 Pfizer Inc. Corporation Information
11.14.2 Pfizer Inc. Business Overview
11.14.3 Pfizer Inc. Anticancer Biologics Product Features and Attributes
11.14.4 Pfizer Inc. Anticancer Biologics Revenue and Gross Margin (2021-2026)
11.14.5 Pfizer Inc. Recent Developments
11.15 GSK plc
11.15.1 GSK plc Corporation Information
11.15.2 GSK plc Business Overview
11.15.3 GSK plc Anticancer Biologics Product Features and Attributes
11.15.4 GSK plc Anticancer Biologics Revenue and Gross Margin (2021-2026)
11.15.5 GSK plc Recent Developments
11.16 Regeneron Pharmaceuticals, Inc.
11.16.1 Regeneron Pharmaceuticals, Inc. Corporation Information
11.16.2 Regeneron Pharmaceuticals, Inc. Business Overview
11.16.3 Regeneron Pharmaceuticals, Inc. Anticancer Biologics Product Features and Attributes
11.16.4 Regeneron Pharmaceuticals, Inc. Anticancer Biologics Revenue and Gross Margin (2021-2026)
11.16.5 Regeneron Pharmaceuticals, Inc. Recent Developments
11.17 Innovent Biologics, Inc.
11.17.1 Innovent Biologics, Inc. Corporation Information
11.17.2 Innovent Biologics, Inc. Business Overview
11.17.3 Innovent Biologics, Inc. Anticancer Biologics Product Features and Attributes
11.17.4 Innovent Biologics, Inc. Anticancer Biologics Revenue and Gross Margin (2021-2026)
11.17.5 Innovent Biologics, Inc. Recent Developments
11.18 Jiangsu Hengrui Pharmaceuticals Co., Ltd.
11.18.1 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Corporation Information
11.18.2 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Business Overview
11.18.3 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anticancer Biologics Product Features and Attributes
11.18.4 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anticancer Biologics Revenue and Gross Margin (2021-2026)
11.18.5 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Recent Developments
11.19 Shanghai Junshi Biosciences Co., Ltd.
11.19.1 Shanghai Junshi Biosciences Co., Ltd. Corporation Information
11.19.2 Shanghai Junshi Biosciences Co., Ltd. Business Overview
11.19.3 Shanghai Junshi Biosciences Co., Ltd. Anticancer Biologics Product Features and Attributes
11.19.4 Shanghai Junshi Biosciences Co., Ltd. Anticancer Biologics Revenue and Gross Margin (2021-2026)
11.19.5 Shanghai Junshi Biosciences Co., Ltd. Recent Developments
11.20 Akeso, Inc.
11.20.1 Akeso, Inc. Corporation Information
11.20.2 Akeso, Inc. Business Overview
11.20.3 Akeso, Inc. Anticancer Biologics Product Features and Attributes
11.20.4 Akeso, Inc. Anticancer Biologics Revenue and Gross Margin (2021-2026)
11.20.5 Akeso, Inc. Recent Developments
11.21 Shanghai Henlius Biotech, Inc.
11.21.1 Shanghai Henlius Biotech, Inc. Corporation Information
11.21.2 Shanghai Henlius Biotech, Inc. Business Overview
11.21.3 Shanghai Henlius Biotech, Inc. Anticancer Biologics Product Features and Attributes
11.21.4 Shanghai Henlius Biotech, Inc. Anticancer Biologics Revenue and Gross Margin (2021-2026)
11.21.5 Shanghai Henlius Biotech, Inc. Recent Developments
11.22 RemeGen Co., Ltd.
11.22.1 RemeGen Co., Ltd. Corporation Information
11.22.2 RemeGen Co., Ltd. Business Overview
11.22.3 RemeGen Co., Ltd. Anticancer Biologics Product Features and Attributes
11.22.4 RemeGen Co., Ltd. Anticancer Biologics Revenue and Gross Margin (2021-2026)
11.22.5 RemeGen Co., Ltd. Recent Developments
11.23 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
11.23.1 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Corporation Information
11.23.2 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Business Overview
11.23.3 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anticancer Biologics Product Features and Attributes
11.23.4 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anticancer Biologics Revenue and Gross Margin (2021-2026)
11.23.5 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Recent Developments
11.24 Sino Biopharmaceutical Limited
11.24.1 Sino Biopharmaceutical Limited Corporation Information
11.24.2 Sino Biopharmaceutical Limited Business Overview
11.24.3 Sino Biopharmaceutical Limited Anticancer Biologics Product Features and Attributes
11.24.4 Sino Biopharmaceutical Limited Anticancer Biologics Revenue and Gross Margin (2021-2026)
11.24.5 Sino Biopharmaceutical Limited Recent Developments
11.25 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
11.25.1 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Corporation Information
11.25.2 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Business Overview
11.25.3 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Anticancer Biologics Product Features and Attributes
11.25.4 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Anticancer Biologics Revenue and Gross Margin (2021-2026)
11.25.5 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Recent Developments
11.26 Jiangsu Alphamab Biopharmaceuticals Co., Ltd.
11.26.1 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Corporation Information
11.26.2 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Business Overview
11.26.3 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Anticancer Biologics Product Features and Attributes
11.26.4 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Anticancer Biologics Revenue and Gross Margin (2021-2026)
11.26.5 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Recent Developments

12 Anticancer Biologics Value Chain and Ecosystem Analysis
12.1 Anticancer Biologics Value Chain (Ecosystem Structure)
12.2 Upstream Analysis
12.2.1 Key Technologies, Platforms and Infrastructure
12.3 Midstream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Anticancer Biologics Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Anticancer Biologics Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Anticancer Biologics Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Anticancer Biologics Market Size Growth Rate by Target, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Anticancer Biologics Market Size Growth Rate by Route of Administration, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Anticancer Biologics Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Anticancer Biologics Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Anticancer Biologics Revenue by Region (US$ Million), 2021-2026
Table 7. Global Anticancer Biologics Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global Anticancer Biologics Revenue by Players (US$ Million), 2021-2026
Table 10. Global Anticancer Biologics Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Anticancer Biologics Revenue, 2025
Table 13. Global Anticancer Biologics Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global Anticancer Biologics Companies Headquarters
Table 15. Global Anticancer Biologics Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global Anticancer Biologics Revenue by Type (US$ Million), 2021-2026
Table 19. Global Anticancer Biologics Revenue by Type (US$ Million), 2027-2032
Table 20. Global Anticancer Biologics Revenue by Target (US$ Million), 2021-2026
Table 21. Global Anticancer Biologics Revenue by Target (US$ Million), 2027-2032
Table 22. Global Anticancer Biologics Revenue by Route of Administration (US$ Million), 2021-2026
Table 23. Global Anticancer Biologics Revenue by Route of Administration (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global Anticancer Biologics Revenue by Application (US$ Million), 2021-2026
Table 26. Global Anticancer Biologics Revenue by Application (US$ Million), 2027-2032
Table 27. Anticancer Biologics High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by Application
Table 30. North America Anticancer Biologics Growth Accelerators and Market Barriers
Table 31. North America Anticancer Biologics Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe Anticancer Biologics Growth Accelerators and Market Barriers
Table 33. Europe Anticancer Biologics Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific Anticancer Biologics Growth Accelerators and Market Barriers
Table 35. Asia-Pacific Anticancer Biologics Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America Anticancer Biologics Investment Opportunities and Key Challenges
Table 37. Central and South America Anticancer Biologics Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa Anticancer Biologics Investment Opportunities and Key Challenges
Table 39. Middle East and Africa Anticancer Biologics Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. AbbVie Inc. Corporation Information
Table 41. AbbVie Inc. Description and Major Businesses
Table 42. AbbVie Inc. Product Features and Attributes
Table 43. AbbVie Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. AbbVie Inc. Revenue Proportion by Product in 2025
Table 45. AbbVie Inc. Revenue Proportion by Application in 2025
Table 46. AbbVie Inc. Revenue Proportion by Geographic Area in 2025
Table 47. AbbVie Inc. Anticancer Biologics SWOT Analysis
Table 48. AbbVie Inc. Recent Developments
Table 49. Johnson & Johnson Corporation Information
Table 50. Johnson & Johnson Description and Major Businesses
Table 51. Johnson & Johnson Product Features and Attributes
Table 52. Johnson & Johnson Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. Johnson & Johnson Revenue Proportion by Product in 2025
Table 54. Johnson & Johnson Revenue Proportion by Application in 2025
Table 55. Johnson & Johnson Revenue Proportion by Geographic Area in 2025
Table 56. Johnson & Johnson Anticancer Biologics SWOT Analysis
Table 57. Johnson & Johnson Recent Developments
Table 58. Novartis AG Corporation Information
Table 59. Novartis AG Description and Major Businesses
Table 60. Novartis AG Product Features and Attributes
Table 61. Novartis AG Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. Novartis AG Revenue Proportion by Product in 2025
Table 63. Novartis AG Revenue Proportion by Application in 2025
Table 64. Novartis AG Revenue Proportion by Geographic Area in 2025
Table 65. Novartis AG Anticancer Biologics SWOT Analysis
Table 66. Novartis AG Recent Developments
Table 67. Gilead Sciences, Inc. Corporation Information
Table 68. Gilead Sciences, Inc. Description and Major Businesses
Table 69. Gilead Sciences, Inc. Product Features and Attributes
Table 70. Gilead Sciences, Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. Gilead Sciences, Inc. Revenue Proportion by Product in 2025
Table 72. Gilead Sciences, Inc. Revenue Proportion by Application in 2025
Table 73. Gilead Sciences, Inc. Revenue Proportion by Geographic Area in 2025
Table 74. Gilead Sciences, Inc. Anticancer Biologics SWOT Analysis
Table 75. Gilead Sciences, Inc. Recent Developments
Table 76. Roche Corporation Information
Table 77. Roche Description and Major Businesses
Table 78. Roche Product Features and Attributes
Table 79. Roche Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. Roche Revenue Proportion by Product in 2025
Table 81. Roche Revenue Proportion by Application in 2025
Table 82. Roche Revenue Proportion by Geographic Area in 2025
Table 83. Roche Anticancer Biologics SWOT Analysis
Table 84. Roche Recent Developments
Table 85. Bristol-Myers Squibb Company Corporation Information
Table 86. Bristol-Myers Squibb Company Description and Major Businesses
Table 87. Bristol-Myers Squibb Company Product Features and Attributes
Table 88. Bristol-Myers Squibb Company Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. Bristol-Myers Squibb Company Recent Developments
Table 90. Amgen Inc. Corporation Information
Table 91. Amgen Inc. Description and Major Businesses
Table 92. Amgen Inc. Product Features and Attributes
Table 93. Amgen Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. Amgen Inc. Recent Developments
Table 95. AstraZeneca plc Corporation Information
Table 96. AstraZeneca plc Description and Major Businesses
Table 97. AstraZeneca plc Product Features and Attributes
Table 98. AstraZeneca plc Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. AstraZeneca plc Recent Developments
Table 100. Merck & Co., Inc. Corporation Information
Table 101. Merck & Co., Inc. Description and Major Businesses
Table 102. Merck & Co., Inc. Product Features and Attributes
Table 103. Merck & Co., Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. Merck & Co., Inc. Recent Developments
Table 105. Takeda Pharmaceutical Company Limited Corporation Information
Table 106. Takeda Pharmaceutical Company Limited Description and Major Businesses
Table 107. Takeda Pharmaceutical Company Limited Product Features and Attributes
Table 108. Takeda Pharmaceutical Company Limited Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. Takeda Pharmaceutical Company Limited Recent Developments
Table 110. Merck KGaA Corporation Information
Table 111. Merck KGaA Description and Major Businesses
Table 112. Merck KGaA Product Features and Attributes
Table 113. Merck KGaA Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. Merck KGaA Recent Developments
Table 115. Eli Lilly and Company Corporation Information
Table 116. Eli Lilly and Company Description and Major Businesses
Table 117. Eli Lilly and Company Product Features and Attributes
Table 118. Eli Lilly and Company Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. Eli Lilly and Company Recent Developments
Table 120. Ono Pharmaceutical Co., Ltd. Corporation Information
Table 121. Ono Pharmaceutical Co., Ltd. Description and Major Businesses
Table 122. Ono Pharmaceutical Co., Ltd. Product Features and Attributes
Table 123. Ono Pharmaceutical Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. Ono Pharmaceutical Co., Ltd. Recent Developments
Table 125. Pfizer Inc. Corporation Information
Table 126. Pfizer Inc. Description and Major Businesses
Table 127. Pfizer Inc. Product Features and Attributes
Table 128. Pfizer Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. Pfizer Inc. Recent Developments
Table 130. GSK plc Corporation Information
Table 131. GSK plc Description and Major Businesses
Table 132. GSK plc Product Features and Attributes
Table 133. GSK plc Revenue (US$ Million) and Gross Margin (2021-2026)
Table 134. GSK plc Recent Developments
Table 135. Regeneron Pharmaceuticals, Inc. Corporation Information
Table 136. Regeneron Pharmaceuticals, Inc. Description and Major Businesses
Table 137. Regeneron Pharmaceuticals, Inc. Product Features and Attributes
Table 138. Regeneron Pharmaceuticals, Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 139. Regeneron Pharmaceuticals, Inc. Recent Developments
Table 140. Innovent Biologics, Inc. Corporation Information
Table 141. Innovent Biologics, Inc. Description and Major Businesses
Table 142. Innovent Biologics, Inc. Product Features and Attributes
Table 143. Innovent Biologics, Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 144. Innovent Biologics, Inc. Recent Developments
Table 145. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Corporation Information
Table 146. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Description and Major Businesses
Table 147. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Product Features and Attributes
Table 148. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 149. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Recent Developments
Table 150. Shanghai Junshi Biosciences Co., Ltd. Corporation Information
Table 151. Shanghai Junshi Biosciences Co., Ltd. Description and Major Businesses
Table 152. Shanghai Junshi Biosciences Co., Ltd. Product Features and Attributes
Table 153. Shanghai Junshi Biosciences Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 154. Shanghai Junshi Biosciences Co., Ltd. Recent Developments
Table 155. Akeso, Inc. Corporation Information
Table 156. Akeso, Inc. Description and Major Businesses
Table 157. Akeso, Inc. Product Features and Attributes
Table 158. Akeso, Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 159. Akeso, Inc. Recent Developments
Table 160. Shanghai Henlius Biotech, Inc. Corporation Information
Table 161. Shanghai Henlius Biotech, Inc. Description and Major Businesses
Table 162. Shanghai Henlius Biotech, Inc. Product Features and Attributes
Table 163. Shanghai Henlius Biotech, Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 164. Shanghai Henlius Biotech, Inc. Recent Developments
Table 165. RemeGen Co., Ltd. Corporation Information
Table 166. RemeGen Co., Ltd. Description and Major Businesses
Table 167. RemeGen Co., Ltd. Product Features and Attributes
Table 168. RemeGen Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 169. RemeGen Co., Ltd. Recent Developments
Table 170. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Corporation Information
Table 171. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Description and Major Businesses
Table 172. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Product Features and Attributes
Table 173. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 174. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Recent Developments
Table 175. Sino Biopharmaceutical Limited Corporation Information
Table 176. Sino Biopharmaceutical Limited Description and Major Businesses
Table 177. Sino Biopharmaceutical Limited Product Features and Attributes
Table 178. Sino Biopharmaceutical Limited Revenue (US$ Million) and Gross Margin (2021-2026)
Table 179. Sino Biopharmaceutical Limited Recent Developments
Table 180. Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Corporation Information
Table 181. Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Description and Major Businesses
Table 182. Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Product Features and Attributes
Table 183. Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 184. Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Recent Developments
Table 185. Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Corporation Information
Table 186. Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Description and Major Businesses
Table 187. Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Product Features and Attributes
Table 188. Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 189. Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Recent Developments
Table 190. Technologies, Platforms and Infrastructure
Table 191. Distributors List
Table 192. Market Trends and Market Evolution
Table 193. Market Drivers and Opportunities
Table 194. Market Challenges, Risks, and Restraints
Table 195. Research Programs/Design for This Report
Table 196. Key Data Information from Secondary Sources
Table 197. Key Data Information from Primary Sources

List of Figures
Figure 1. Global Anticancer Biologics Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. Antibody Therapies Product Picture
Figure 3. Antibody-Drug Conjugates (ADCs) Product Picture
Figure 4. Cell Therapies Product Picture
Figure 5. Cancer Vaccines and Oncolytic Viruses Product Picture
Figure 6. Others Product Picture
Figure 7. Global Anticancer Biologics Market Size Growth Rate by Target, 2021 vs 2025 vs 2032 (US$ Million)
Figure 8. Immune Checkpoint Targets Product Picture
Figure 9. Solid Tumor-Associated Targets Product Picture
Figure 10. Hematologic Tumor Targets Product Picture
Figure 11. Angiogenesis-Related Targets Product Picture
Figure 12. Others Product Picture
Figure 13. Global Anticancer Biologics Market Size Growth Rate by Route of Administration, 2021 vs 2025 vs 2032 (US$ Million)
Figure 14. Intravenous Administration Product Picture
Figure 15. Subcutaneous Administration Product Picture
Figure 16. Cell Infusion Product Picture
Figure 17. Intratumoral Administration Product Picture
Figure 18. Others Product Picture
Figure 19. Global Anticancer Biologics Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 20. Lung Cancer
Figure 21. Breast Cancer
Figure 22. Hematologic Cancers
Figure 23. Gastrointestinal Cancers
Figure 24. Others
Figure 25. Anticancer Biologics Report Years Considered
Figure 26. Global Anticancer Biologics Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 27. Global Anticancer Biologics Revenue (US$ Million), 2021-2032
Figure 28. Global Anticancer Biologics Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 29. Global Anticancer Biologics Revenue-Based Market Share by Region (2021-2032)
Figure 30. Global Anticancer Biologics Revenue-Based Market Share Ranking (2025)
Figure 31. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 32. Antibody Therapies Revenue-Based Market Share by Player in 2025
Figure 33. Antibody-Drug Conjugates (ADCs) Revenue-Based Market Share by Player in 2025
Figure 34. Cell Therapies Revenue-Based Market Share by Player in 2025
Figure 35. Cancer Vaccines and Oncolytic Viruses Revenue-Based Market Share by Player in 2025
Figure 36. Others Revenue-Based Market Share by Player in 2025
Figure 37. Global Anticancer Biologics Revenue-Based Market Share by Type (2021-2032)
Figure 38. Global Anticancer Biologics Revenue-Based Market Share by Target (2021-2032)
Figure 39. Global Anticancer Biologics Revenue-Based Market Share by Route of Administration (2021-2032)
Figure 40. Global Anticancer Biologics Revenue-Based Market Share by Application (2021-2032)
Figure 41. North America Anticancer Biologics Revenue YoY (US$ Million), 2021-2032
Figure 42. North America Top 5 Players Anticancer Biologics Revenue (US$ Million) in 2025
Figure 43. North America Anticancer Biologics Revenue (US$ Million) by Application (2021-2032)
Figure 44. US Anticancer Biologics Revenue (US$ Million), 2021-2032
Figure 45. Canada Anticancer Biologics Revenue (US$ Million), 2021-2032
Figure 46. Mexico Anticancer Biologics Revenue (US$ Million), 2021-2032
Figure 47. Europe Anticancer Biologics Revenue YoY (US$ Million), 2021-2032
Figure 48. Europe Top 5 Players Anticancer Biologics Revenue (US$ Million) in 2025
Figure 49. Europe Anticancer Biologics Revenue (US$ Million) by Application (2021-2032)
Figure 50. Germany Anticancer Biologics Revenue (US$ Million), 2021-2032
Figure 51. France Anticancer Biologics Revenue (US$ Million), 2021-2032
Figure 52. U.K. Anticancer Biologics Revenue (US$ Million), 2021-2032
Figure 53. Italy Anticancer Biologics Revenue (US$ Million), 2021-2032
Figure 54. Russia Anticancer Biologics Revenue (US$ Million), 2021-2032
Figure 55. Asia-Pacific Anticancer Biologics Revenue YoY (US$ Million), 2021-2032
Figure 56. Asia-Pacific Top 8 Players Anticancer Biologics Revenue (US$ Million) in 2025
Figure 57. Asia-Pacific Anticancer Biologics Revenue (US$ Million) by Application (2021-2032)
Figure 58. Indonesia Anticancer Biologics Revenue (US$ Million), 2021-2032
Figure 59. Japan Anticancer Biologics Revenue (US$ Million), 2021-2032
Figure 60. South Korea Anticancer Biologics Revenue (US$ Million), 2021-2032
Figure 61. Australia Anticancer Biologics Revenue (US$ Million), 2021-2032
Figure 62. India Anticancer Biologics Revenue (US$ Million), 2021-2032
Figure 63. Indonesia Anticancer Biologics Revenue (US$ Million), 2021-2032
Figure 64. Vietnam Anticancer Biologics Revenue (US$ Million), 2021-2032
Figure 65. Malaysia Anticancer Biologics Revenue (US$ Million), 2021-2032
Figure 66. Philippines Anticancer Biologics Revenue (US$ Million), 2021-2032
Figure 67. Singapore Anticancer Biologics Revenue (US$ Million), 2021-2032
Figure 68. Central and South America Anticancer Biologics Revenue YoY (US$ Million), 2021-2032
Figure 69. Central and South America Top 5 Players Anticancer Biologics Revenue (US$ Million) in 2025
Figure 70. Central and South America Anticancer Biologics Revenue (US$ Million) by Application (2021-2032)
Figure 71. Brazil Anticancer Biologics Revenue (US$ Million), 2021-2032
Figure 72. Argentina Anticancer Biologics Revenue (US$ Million), 2021-2032
Figure 73. Middle East and Africa Anticancer Biologics Revenue YoY (US$ Million), 2021-2032
Figure 74. Middle East and Africa Top 5 Players Anticancer Biologics Revenue (US$ Million) in 2025
Figure 75. Middle East and Africa Anticancer Biologics Revenue (US$ Million) by Application (2021-2032)
Figure 76. GCC Countries Anticancer Biologics Revenue (US$ Million), 2021-2032
Figure 77. Israel Anticancer Biologics Revenue (US$ Million), 2021-2032
Figure 78. Egypt Anticancer Biologics Revenue (US$ Million), 2021-2032
Figure 79. South Africa Anticancer Biologics Revenue (US$ Million), 2021-2032
Figure 80. Anticancer Biologics Value Chain Mapping
Figure 81. Channels of Distribution (Direct Vs Distribution)
Figure 82. Bottom-up and Top-down Approaches for This Report
Figure 83. Data Triangulation
Figure 84. Key Executives Interviewed